Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 18/20 | 0.58 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085646 | 0.82 | PARG (0.63) | PARGGRIN1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL17825073 | 0.79 | PARG (0.71) | PARG | |
| Hydrochloric Acid SCHEMBL28850464 | 0.78 | PARG (0.70) | PARG | |
| SCHEMBL17824929 | 0.78 | ALDH1A1 (0.66) | PARGKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL17824743 | 0.74 | GRIN1 (0.58) | PARGGRIN1GRIN2BKDM4EALDH1A1 | |
| SCHEMBL17825010 | 0.74 | PARG (1.00) | PARG | |
| SCHEMBL17824558 | 0.74 | PARG (1.00) | PARG | |
| SCHEMBL17824605 | 0.73 | PARG (1.00) | PARG | |
| SCHEMBL17824601 | 0.72 | PARG (1.00) | PARG | |
| SCHEMBL17824894 | 0.72 | PARG (0.84) | PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016242-A1 | 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG | PARG, PARP15, PARP12 | PARG 1/4885GRIN1 4161/4885GRIN2B 2505/4885 |
| US-10239843-B2 | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG | PARG, PARP15, PARP12 | PARG 1/4885GRIN1 4161/4885GRIN2B 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.